Norris Medicines Ltd Stock Hits 52-Week Low Amidst Continued Downtrend

Recent Price Movement and Market Context

The stock of Norris Medicines Ltd has been on a declining trajectory for the past three consecutive trading sessions, losing 7.23% over this period. Today’s fall of 2.57% further extended the stock’s underperformance relative to its Trading & Distributors sector, which outpaced Norris Medicines by 0.78% on the day. The new 52-week low of Rs.13.5 is a notable drop from its 52-week high of Rs.24.65, representing a decline of approximately 45.2% over the past year.

Technical indicators also highlight the bearish momentum, with the stock currently trading below all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day. This broad-based weakness in moving averages signals a lack of short- and long-term price support.

Meanwhile, the broader market has also faced pressure. The Sensex opened flat but sharply declined by 860.12 points, or 1.08%, closing at 82,347.26. Despite this, the Sensex remains within 4.63% of its 52-week high of 86,159.02. The index has experienced a three-week consecutive fall, losing 3.98% in this period, and is trading below its 50-day moving average, although the 50DMA remains above the 200DMA, indicating some underlying resilience in the broader market.

Financial Performance and Fundamental Assessment

Norris Medicines Ltd’s financial metrics reveal several areas of concern that have contributed to the stock’s subdued performance. The company’s long-term fundamentals are weak, as reflected in its negative book value and a Mojo Grade of Strong Sell, upgraded from Sell on 30 June 2025. The Mojo Score stands at 12.0, underscoring the company’s challenging outlook.

Over the last five years, the company’s net sales have declined at an annualised rate of 2.13%, while operating profit has remained flat, indicating stagnation in core business growth. The company’s debt profile is also notable; despite being classified as a high-debt company, the average debt-to-equity ratio is reported as zero, which may reflect accounting nuances or off-balance-sheet liabilities.

Quarterly results for September 2025 further highlight the company’s difficulties. The Profit Before Depreciation, Interest, and Taxes (PBDIT) was negative at Rs.-0.49 crore, while Profit Before Tax excluding other income (PBT less OI) stood at Rs.-0.72 crore. Earnings per share (EPS) for the quarter were also negative at Rs.-0.73, marking the lowest quarterly figures recorded recently.

Valuation and Risk Considerations

The stock’s valuation metrics indicate elevated risk. Norris Medicines Ltd is trading at levels considered risky relative to its historical average valuations. Over the past year, the stock has generated a negative return of 35.43%, while profits have contracted by 71%. This combination of declining profitability and share price depreciation has contributed to the company’s current market standing.

In addition to the negative EBITDA, the company’s long-term performance has been below par. It has underperformed the BSE500 index over the last three years, one year, and three months, signalling persistent challenges in maintaining competitive performance within its sector and the broader market.

Shareholding patterns reveal that the majority of shares are held by non-institutional investors, which may affect liquidity and trading dynamics.

Summary of Key Metrics

To summarise, Norris Medicines Ltd’s stock price has declined to Rs.13.5, its lowest level in 52 weeks, reflecting a combination of weak financial performance, negative earnings, and subdued market sentiment. The company’s Mojo Grade of Strong Sell and a Mojo Score of 12.0 highlight the challenges faced. The stock’s underperformance relative to the Sensex, which has gained 6.74% over the past year, further emphasises the divergence in performance.

With a market capitalisation grade of 4 and a debt-to-equity ratio averaging zero despite classification as a high-debt company, the financial structure presents complexities. The negative quarterly earnings and declining sales growth over five years add to the cautious outlook.

Overall, the stock’s current position at a 52-week low is a reflection of sustained pressures across multiple dimensions, including profitability, valuation, and market dynamics.

Unlock special upgrade rates for a limited period. Start Saving Now →